Volume 9 Supplement 1
Procalcitonin as a marker of bacterial sepsis in immunocompromised patients
© Gatserelia et al; licensee BioMed Central Ltd. 2012
Published: 25 May 2012
Procalcitonin (PCT) is a recently described marker of severe sepsis. It was decided to assess the value of PCT as a marker of secondary infection in patients infected with HIV in Georgian AIDS Center.
Materials and methods
PCT plasma levels were measured by quantitative assay BRAHMS-Biomérieux using the VIDAS analyser in a prospective study in 135 HIV-infected individuals: 87 asymptomatic and 48 with lever or suspected secondary infections.
The baseline plasma level of PCT was (0.5 ng/ml +/- 0.5), even in the latest stages of the disease, and did not differ from the values of healthy subjects (0.54 ng/ml +/- 0.1). EDTA-treated whole blood was collected from patients before starting specific antimicrobial therapy. No elevation of PCT level was detected in HIV-infected patients with evolving secondary infections including PCP (n = 4), cerebral toxoplasmosis (n = 5), viral infections (n = 9), mycobacterial infections (n = 4), localized bacterial (n = 13) and fungal infections (n = 4), and in various associated infectious and non-infectious febrile events (n = 15). All these plasma values were lower than 2 ng/ml. In contrast, high PCT plasma levels were detected in one HIV-infected patient with a septicaemic influenza infection (17 ng/ml) and another one with a septicaemic Pneudomonas aeruginosa infection (46 ng/ ml), PCT values decreased rapidly under appropriate therapy.
We found that PCT is a specific marker of bacterial sepsis in HIV-infected patients, as no increase in other secondary infections could be detected in those patients. A rapid determination of PCT level could be useful to verify or refute bacterial sepsis for a better management of febrile HIV-infected patients.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.